Welcome to our dedicated page for Becton Dickinson & news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & stock.
Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (NYSE: BDX) reported that its STANCE clinical trial of GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture has surpassed a key enrollment milestone. The study has treated 274 patients across 33 active U.S. sites, triggering the first planned interim analysis. This exceeds 50% of the trial’s maximum planned enrollment, which under the adaptive design is expected to range from 250 to 530 patients.
The prospective, randomized, controlled, multi-center trial compares GalaFLEX LITE™ Scaffold plus implant revision against conventional revision surgery without a matrix or ADM, using a 2:1 randomization. According to BD, STANCE is intended to generate safety and efficacy data to support a potential new breast indication and a future FDA Premarket Approval application for GalaFLEX LITE™ Scaffold, which is based on BD’s poly-4-hydroxybutyrate (P4HB) bioabsorbable soft tissue support platform.
BD (NYSE: BDX) announced it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. Eastern Time. A live webcast and replay of the presentation will be available via the BD investor relations website, investors.bd.com.
BD (NYSE: BDX) announced the appointment of Gary Sorsher as executive vice president and chief quality officer, effective September 8. Sorsher has more than 30 years of experience leading quality organizations at global MedTech companies and most recently served as chief quality officer at Edwards Lifesciences.
BD also stated that Jeffrey (Jeff) Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with the company. According to BD, Silvestri helped strengthen the company’s quality foundation and advance quality capabilities across the enterprise.
BD (NYSE: BDX) reported completion of enrollment in the landmark PREVENT clinical trial, a large randomized study evaluating Phasix™ Mesh for prevention of incisional hernias after elective open midline abdominal surgery in high‑risk patients. The trial enrolled 477 patients across 32 sites in the United States and Europe.
According to BD, PREVENT is the first large randomized study of prophylactic reinforcement with a resorbable mesh for this complication, for which no products are currently approved. Patients will be followed to a primary endpoint at 24 months, with additional follow‑up through five years. The company expects study data to support a planned submission to the U.S. Food and Drug Administration for this indication.
BD (NYSE: BDX) reported fiscal Q3 2026 revenue of $4.983 billion, up 5.4% as reported and 4.4% FX-neutral. GAAP diluted EPS from continuing operations was $1.64 (up 4.5%), and adjusted diluted EPS was $3.23 (up 4.9%).
Year-to-date, cash from continuing operations reached $2.1 billion (+33.3%) and free cash flow $1.7 billion (+44.6%). All four segments grew mid-single digits, led by BioPharma Systems and Interventional. Following the February 2026 spin-off of its Biosciences and Diagnostic Solutions business to combine with Waters, BD now reports four segments on a continuing-operations basis.
BD updated full-year 2026 guidance, maintaining low single-digit plus GAAP revenue growth and low single-digit FX-neutral revenue growth, while raising the midpoint of adjusted diluted EPS guidance to $12.62–$12.72 from $12.52–$12.72, reflecting ongoing momentum in its “New BD” MedTech-focused portfolio.
BD (NYSE: BDX) and EMS, a leading Brazilian pharmaceutical company, announced a collaboration to launch an EMS semaglutide therapy in Brazil using the BD Vystra™ Injection Pen platform. The partnership aims to improve access to GLP‑1 treatments for chronic metabolic diseases such as obesity and type 2 diabetes.
According to BD, the Vystra pen offers an intuitive, research-backed design to support safe, accurate and consistent self-injection, addressing patient challenges with ease of use, confidence and adherence. EMS highlights that co-creation with BD helps meet the needs of Brazilian clinicians and patients.
BD (NYSE: BDX) announced that its Board of Directors declared a quarterly cash dividend of $1.05 per common share. The dividend is payable on September 30, 2026, to shareholders of record as of September 9, 2026. According to BD, the indicated annual dividend rate is $4.20 per share.
BD (NYSE: BDX) announced that Dr. Michael (Mike) Garrison, executive vice president and president of the Medical Essentials and BioPharma Systems segments, intends to retire after more than 20 years with the company, effective Oct. 2. Garrison has led multiple major businesses at BD, including the Medical segment, Medication Management Solutions and Surgery.
He will remain in his current role through the end of the fiscal year. BD has launched a comprehensive search for the next president of Medical Essentials, while BioPharma Systems will begin reporting directly to Chairman, CEO and President Tom Polen, reflecting its strategic role as a growth driver and streamlining BD’s operating model.
BD (NYSE:BDX) announced that management will host an audio webcast at 8 a.m. ET on Thursday, August 6, 2026, to discuss financial results for its third quarter of fiscal 2026, ended June 30, 2026, and provide an update on operations and strategy.
The live webcast and replay will be available on BD's investor relations website, where the related earnings news release and presentation materials will also be posted.
BD (NYSE:BDX) received a Vizient Innovative Technology contract for its BD CentroVena One™ Insertion System, the first all-in-one central venous catheter insertion system.
The system integrates multiple components to simplify central line placement, with 30% fewer steps and up to 50% lower maximum procedure time in simulation.